# USC Norris Comprehensive Cancer Center

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/usc-norris-comprehensive-cancer-center/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 92.5 |
| Citations | 747,807 |
| City | Los Angeles |
| Country | US |
| Description | USC Norris Comprehensive Cancer Center is a research organisation in Los Angeles, US. OpenAlex records 6,407 works and 747,807 citations for it. 908 researchers list it as their most recent affiliation. |
| Homepage | https://uscnorriscancer.usc.edu |
| OpenAlex ID | https://openalex.org/I4210117038 |
| Region | California |
| Researchers | 908 |
| ROR ID | https://ror.org/01nmyfr60 |
| Type | healthcare |
| Works | 6,407 |

## University papers

- [Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma](https://scholariq.org/papers/pembrolizumab-as-second-line-therapy-for-advanced-urothelial-carcinoma/)
- [Intermittent versus Continuous Androgen Deprivation in Prostate Cancer](https://scholariq.org/papers/intermittent-versus-continuous-androgen-deprivation-in-prostate-cancer/)
- [Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease](https://scholariq.org/papers/fasting-mimicking-diet-and-markers-risk-factors-for-aging-diabetes-cancer-and/)
- [Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/circulating-tumor-cell-counts-are-prognostic-of-overall-survival-in-swog-s0421-a/)
- [Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-placebo-as-post-nephrectomy-adjuvant-therapy-for-clear-cell/)
- [Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial](https://scholariq.org/papers/axitinib-versus-placebo-as-an-adjuvant-treatment-of-renal-cell-carcinoma-results/)

## University top topics

Showing 8 of 25.

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Epigenetics and DNA Methylation](https://scholariq.org/topics/epigenetics-and-dna-methylation/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.